Skip to content

Author

Sarfaraz K. Niazi

We have 8 of 277 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Computational design and translational development of TCR-mimic scFv antibodies for peptide-HLA neoantigen targeting

Single-chain variable fragments (scFvs) penetrate tissue more effectively than full antibodies and are simpler to produce, but the mutant proteins that define a tumor are predominantly intracellular and therefore inaccessible to conventional antibodies. What is accessible is the mutation-derived peptide displayed on ce...

Sarfaraz K. Niazi, Matthias Magoola, Zamara Mariam · 0 citations
Open access Oct 2026

Reference-Anchored Equivalence: A Unified Scientific Framework for the Approval of Follow-On Drugs and Biological Products

Follow-on approval processes in the United States are conducted through three distinct legal pathways: abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act; applications under section 505(b)(2); and biosimilar applications under section 351(k) of the Public Health Service A...

Sarfaraz K. Niazi · 0 citations
Review Open access Oct 2026

Current translational perspectives for diagnosis and individualized therapy in rare genetic diseases

Rare diseases affect hundreds of millions of individuals worldwide, primarily resulting from genetic factors, with many presenting during childhood. Advances in genome sequencing increasingly enable identification of the responsible gene in more patients; however, only a limited selection of therapies exists to correct...

Sarfaraz K. Niazi · 0 citations
Review Open access Aug 2026

From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines

This hypothesis framework proposes seven sequential gates for antigen-defined, HLA-restricted T-cell vaccines: tumor specificity, natural peptide–HLA presentation, population coverage, persistence under immune selection, selective T-cell recognition, manufacturability, and randomized clinical benefit.

Sarfaraz K. Niazi · 0 citations
Review Open access Aug 2026

Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatment

It is argued that the hallmarks framework, while historically essential, is no longer sufficient on its own to capture contemporary cancer care, and repositions the discussion around enabling technologies that operate across and beyond individual hallmarks.

Sarfaraz K. Niazi · 0 citations
Review Open access Sep 2026

Explicit Mechanistic Operators in Predictive Virtual Cells: Evidence, Failure Modes, and a Minimum Falsification Framework for Single-Cell Perturbation Prediction

This Perspective asks whether a biologically specified mechanistic operator improves out-of-distribution prediction of single-cell perturbation responses beyond strong simple, relational, transport-based, and learned-dynamical comparators.

Mikołaj Stańczak, Sarfaraz K. Niazi · 0 citations
Open access Jul 2026

Physical feasibility gating in early drug discovery: a decision framework for identifying predictable physical failures, with retrospective illustration

A systematic evaluation of thermodynamic, kinetic, transport, transport, and microenvironmental constraints can identify candidates likely to fail on physical grounds prior to substantial investment in synthesis and translational research, thereby conserving resources for the inherently experimental validation of biolo...

Sarfaraz K. Niazi · 0 citations
#protein folding Open access Aug 2026

Dynamic Protein Structure Paradox: An Integrative Framework for Endpoint-Conditioned Evidentiary Sufficiency in Structure-to-Function Claims

The Dynamic Protein Structure Paradox is defined as the apparent conflict between structural accuracy and functional underdetermination and DPSP is developed as an integrative evidentiary assessment framework rather than a new theory or paradigm.

Sarfaraz K. Niazi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.